Almirall S.A., a global pharmaceutical company specialising in medical dermatology, announces its entry into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828.
Under the agreement, Almirall obtains global rights to develop and commercialise this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases.
Almirall will accelerate the development of the asset to address key dermatological diseases taking responsibility for the global development and future commercialisation in these indications.
Novo Nordisk will receive an upfront payment as well as additional development and commercial milestone payments and tiered royalties based upon future global sales.
NN-8828 is a first-in-class in dermatology, high affinity monoclonal antibody that targets the cytokine IL-21 and has been developed by Novo Nordisk up to Phase ll in non-dermatological indications.
NN-8828 has the potential to block the activation of the downstream signalling pathways of IL-21 and inhibit the pathophysiological functions induced by this cytokine in several immune cells. This differentiated mechanism makes NN-8828 a promising option for the treatment of inflammatory and autoimmune skin disorders.
“This new partnership builds on our novel strategy, and will allow us to explore the innovative approach of IL-21 blockage as a possible new pathway to effectively treat a range of dermatological diseases.” said Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall.
